Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
MERIT-HF
About the Trial
The Metoprolol CR XL Randomized Intervention Trial in Congestive Heart Failure randomized 3,991 patients with moderate heart failure to controlled release metoprolol or placebo on top of standard therapy. The trial stopped early: metoprolol reduced all cause mortality by 34 percent and sudden death by 41 percent. For decades beta blockers were considered forbidden in heart failure because they acutely depress contractility. MERIT-HF, with CIBIS II and COPERNICUS forming the trio, proved chronic beta blockade protects the failing heart from adrenergic toxicity. Beta blockers moved from contraindication to core therapy, one of the great reversals in cardiology.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...